Portola Pharmaceuticals Inc (NASDAQ:PTLA) has been given an average recommendation of “Hold” by the eleven ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $38.75.
Several research firms have weighed in on PTLA. Cowen restated a “buy” rating and set a $45.00 target price on shares of Portola Pharmaceuticals in a research note on Tuesday, November 5th. ValuEngine downgraded Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, October 21st. Zacks Investment Research upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Wednesday, October 9th. Citigroup reduced their price objective on Portola Pharmaceuticals from $51.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Finally, Goldman Sachs Group assumed coverage on Portola Pharmaceuticals in a research report on Friday, November 8th. They issued a “neutral” rating and a $35.00 target price on the stock.
Shares of NASDAQ:PTLA traded up $0.86 during midday trading on Tuesday, hitting $29.21. The stock had a trading volume of 802,604 shares, compared to its average volume of 719,885. The company’s 50-day moving average price is $28.61 and its 200-day moving average price is $28.00. The company has a market capitalization of $2.21 billion, a P/E ratio of -5.83 and a beta of 2.06. The company has a quick ratio of 5.85, a current ratio of 5.88 and a debt-to-equity ratio of 1.25. Portola Pharmaceuticals has a fifty-two week low of $14.81 and a fifty-two week high of $37.95.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.82) by $0.14. Portola Pharmaceuticals had a negative net margin of 275.13% and a negative return on equity of 282.04%. The business had revenue of $36.80 million for the quarter, compared to analyst estimates of $34.64 million. During the same quarter last year, the business posted ($1.08) EPS. The firm’s revenue for the quarter was up 159.2% on a year-over-year basis. Research analysts expect that Portola Pharmaceuticals will post -3.49 EPS for the current fiscal year.
In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $30.00, for a total value of $150,000.00. Following the sale, the director now owns 18,194 shares in the company, valued at $545,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.50% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Los Angeles Capital Management & Equity Research Inc. lifted its holdings in Portola Pharmaceuticals by 45.2% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 18,310 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 5,700 shares during the period. Fisher Asset Management LLC increased its position in Portola Pharmaceuticals by 16.6% during the 2nd quarter. Fisher Asset Management LLC now owns 100,722 shares of the biopharmaceutical company’s stock valued at $2,733,000 after purchasing an additional 14,338 shares during the period. First Trust Advisors LP bought a new position in Portola Pharmaceuticals during the 2nd quarter worth approximately $3,110,000. Aperio Group LLC bought a new position in Portola Pharmaceuticals during the 2nd quarter worth approximately $152,000. Finally, J. L. Bainbridge & Co. Inc. bought a new position in Portola Pharmaceuticals during the 2nd quarter worth approximately $202,000.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Further Reading: How to interpret a stock’s beta number
Receive News & Ratings for Portola Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Portola Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
